XORTX Therapeutics Extends Renal Anti‑Fibrotic Acquisition, Boosts Kidney Disease Pipeline
Read how XORTX Therapeutics extends its renal anti‑fibrotic program acquisition to boost kidney disease treatments and investor prospects.
2 minutes to read
XORTX Therapeutics Inc
XORTX Therapeutics Raises $1.1 Million in Direct Offering Amid Nasdaq Compliance Extension
XORTX Therapeutics has secured $1.1 million in a direct offering to support its development of therapies for metabolic and cardiovascular disorders, while also addressing a Nasdaq bid-price compliance issue with a 180-day extension.
3 minutes to read